Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient
31 August 2019 (00:00 - 00:00)
Organised by:
About the speaker
Institute of Health Biosciences- The University of Tokushima Graduate School, Tokushima (Japan)
6 More presentations in this session
Mr C. Galan (Madrid, ES)
Mrs A. Hoogendoorn (Adelaide, AU)
Doctor G. Detriche (Paris, FR)
Doctor H. Okawa (Nagoya, JP)
Ms L. Lopez Sanz (Madrid, ES)
Access the full session
The Event
ESC Congress 2019
31 August - 4 September 2019
